FINO Enters Florida Cannabis With an Effect-Based Retail Bet

FINO Cannabis has opened its first Florida dispensary in Clermont and lined up a second in Winter Park, stepping into one of the largest but most concentrated medical marijuana markets in the country. The newcomer is betting that a debt-free balance sheet and an effect-based retail model can pull patients away from the handful of large operators that dominate the state.

Getting in wasn’t a matter of filing an application. Florida caps the number of cannabis licenses, so a new entrant has to buy its way in. FINO’s permit traces to the former Planet 13 Florida license, which Planet 13 sold for US$9 million in May 2024, after the state’s Office of Medical Marijuana Use approved the transfer that April. FINO opened the Clermont store in late June 2026, with the Winter Park location expected within a few months.

Why Florida is hard to crack

Florida is one of the few large states that requires cannabis license holders to be vertically integrated: every operator must grow, process and sell its own products, and the state issues no standalone cultivation, manufacturing or retail licenses. That structure raises the cost of entry, because a retailer can’t simply buy inventory from a wholesaler and open a storefront. FINO built its cultivation in Felda, in southwest Florida, to supply its central-Florida stores; the vertical model ties a retailer’s shelves directly to its own harvest.

The permits are also scarce. The state issued its first licenses after voters approved medical marijuana in 2016, and it adds new ones only as the registry grows, at roughly four permits for every 100,000 new patients. FINO applied in a 2023 licensing round and is coming online only now, joining a field of about 25 active operators.

Scale has favored the incumbents. A single Florida license lets an operator open an unlimited number of dispensing locations, which is how the biggest multistate companies built commanding positions. Trulieve alone ran 169 of the state’s roughly 768 dispensing locations in early July 2026, and the largest operators together account for a majority of both locations and dispensed volume, according to OMMU weekly data.

Inside the numbers

The prize is a patient base no other state matches. Florida counted about 936,000 registered medical marijuana patients in early July 2026, roughly 4% of residents and the largest such registry in the country. Annual retail sales ran near $1.89 billion last year, according to cannabis analytics firm Headset, and the state charges no excise tax on medical marijuana, leaving more of each sale with operators.

Demand runs deep. In the week ending July 2, 2026, Florida’s operators dispensed about 454 million milligrams of THC and roughly 159,000 ounces of smokable flower, with Trulieve taking the largest share. For FINO, the case for entry is financial discipline as much as market size. The company was funded privately by family offices and individual backers and carries no legacy debt, an edge in an industry where several operators overextended on stores and leases when capital was cheap, then struggled once financing tightened. FINO says the clean balance sheet lets it move quickly on strong retail sites without the drag of debt service.

The retail bet

FINO’s wager is that Florida dispensaries have converged on a single metric, THC potency, and left part of the patient base underserved. CEO Joe Puglise, who helped run a Colorado multistate operator before founding the company, argues the state’s medical program largely behaves like a recreational one built around high-THC flower and concentrates, while many patients want products aimed at sleep, discomfort or mild relief. The company estimates that a fifth to half of potential patients fall into that group.

Its answer is effect-based merchandising: non-irradiated flower, terpene-forward vapes and live resin, and a “shop by effect” menu instead of one organized around strain names and potency. The stores lean on a hospitality feel and staff trained to guide patients rather than upsell. “We built FINO around the patient experience, from cultivation all the way to the moment someone walks out the door,” Puglise said in announcing the Clermont opening.

Incumbents are sharpening their retail game too. Rival Curaleaf recently added Spanish-language service across its dispensaries, a sign that the largest operators are competing on service, not just shelf space and price.

FINO’s growth plan is deliberately small. Rather than blanket the state, the company says it would rather run 15 profitable, well-placed stores than 50 or 100, competing hard within a tight local radius where it thinks a focused operator can outwork a national chain. That approach will be tested against rivals with far more locations, cultivation capacity and brand recognition, and against the open question of whether Florida ever moves to adult-use sales, which would rewrite the economics for everyone. In a market where scale has been the winning formula, FINO is wagering that how a store sells can count as much as how much it sells.